Arnold Cinman
University of California, Los Angeles
6 Papers
2 Citations
Arnold Cinman is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial
K. Kent Chevli,Neal D. Shore,Andrew Trainer,Angela B. Smith,Daniel Saltzstein,Yaron Ehrlich,Jay D. Raman,Boris Friedman,Richard D’Anna,David L. Morris,Brian Hu,Mark D. Tyson,Alexander Sankin,Max Kates,Jennifer Linehan,Douglas S. Scherr,Steven Kester,Michael Vernia,Karim Chamie,Lawrence Karsh,Arnold Cinman,Andrew Meads,Soumi Lahiri,Madlen Malinowski,Nimrod Gabai,Sunil Raju,Mark P. Schoenberg,Elyse Seltzer,William C. Huang +28 more
TL;DR: Nonsurgical primary chemoablation of LG IR NMIBC using UGN-102 resulted in significant treatment response with sustained durability, and may provide an alternative to repetitive surgery for patients with LG IRNMIBC.
15
Lba02-03 can turbt be avoided? primary chemoablation with a reverse thermal gel containing mitomycin (ugn-102) in patients with low grade intermediate risk non-muscle invasive bladder cancer
William J.S. Huang,K. Kent Chevli,Andrew Trainer,Angela R. Smith,Daniel Saltzstein,Yaron Ehrlich,Boris Friedman,Richard D’Anna,David L. Morris,Brian Hu,Mark D. Tyson,Alexander Sankin,Max Kates,Jennifer Linehan,Douglas S. Scherr,Steven Kester,Michael Verni,Karim Chamie,Lawrence Karsch,Arnold Cinman,Elyse Seltzer,Nimrod Gabai,Robert Kirshoff,Mark P. Schoenberg,Jay D. Raman,Neal D. Shore +25 more
TL;DR: Low grade, intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC) is notable for a high rate of disease recurrence yet low risk of disease progression.
3
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.
Neal D. Shore,F.S. Dela Cruz,Luke Nordquist,Laurence Belkoff,William J. Aronson,Bhupendra M. Tolia,Arnold Cinman,Roohollah Sharifi,Jorge Ortiz,J. Parkin,Shankar Srinivasan,Toni Sarapohja,Matthew R. Smith +12 more
TL;DR: Darolutamide significantly improved metastasis-free survival (MFS) and overall survival (OS) versus placebo in the phase III ARAMIS study as discussed by the authors , in 52 (3.4%) Black/African-American patients, and OS (3 year survival rates: 100 vs 71%) versus placebo.
Abstract PR-07: Efficacy and safety of darolutamide in Black/African American patients from the phase III ARAMIS trial
Neal D. Shore,F.S. Dela Cruz,Luke Nordquist,Laurence Belkoff,William J. Aronson,Bhupendra M. Tolia,Arnold Cinman,Roohollah Sharifi,Jorge Ortiz,J. Parkin,Shankar Srinivasan,Toni Sarapohja,Madison R. Smith +12 more
- 01 Jan 2022
TL;DR: Shore et al. as discussed by the authors presented the efficacy and safety of darolutamide in black and African-American men with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS.
PD43-02 PRIMARY CHEMOABLATION OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER USING UGN-102, A MITOMYCIN-CONTAINING REVERSE THERMAL GEL (OPTIMA II): A PHASE 2b, OPEN-LABEL, SINGLE-ARM TRIAL
K. Chevli,N. Shore,Andrew Trainer,Angela B. Smith,Daniel Saltzstein,Yaron Ehrlich,Jay D. Raman,Boris Friedman,Richard D’Anna,David Morris,Brian Hu,Mark Tyson,Alex Sankin,Max R Kates,Jennifer Linehan,Douglas Scherr,Steven Kester,Michael Verni,Karim Chamie,Lawrence Karsh,Arnold Cinman,Soumi Lahiri,Andrew Meads,M. Malinowski,N. Gabai,Sunil Raju,Elyse Seltzer,Mark P. Schoenberg,William C. Huang +28 more
- 01 Sep 2021